Microparticles are membrane vesicles shed by cells upon activation and/or apoptosis. Microparticles are involved in several processes, including blood coagulation and thrombosis. In addition to their role in the regulation of lipid metabolism, peroxisome proliferator-activated receptor-g (PPAR-g) agonists exert other effects, both dependent on and independent of PPAR-g activation. Some PPAR-g agonists have been linked to an increased risk of thrombotic diseases. We aimed to investigate the potential role of PPAR-g agonists on the generation of procoagulant microparticles by human monocytes/macrophages.
Introduction
Microparticles (MPs), also referred to as ectosomes or microvesicles, are subcellular structures, ranging in size between 50 nm and 1 mm, released by the plasma membrane of activated and apoptotic cells. 1 As well as cytoplasmic content, MPs have complex surface membrane constituents, and it has now become clear that they represent a disseminated storage pool of bioactive effectors and participate both in the maintenance of homeostasis and in the pathogenesis of disease. 1 The processes in which the contribution of MPs has been demonstrated include inflammation, vascular function, angiogenesis and blood coagulation. 2 -5 This list, however, is incomplete, and is being constantly updated. The mechanisms whereby MPs promote blood coagulation are at least two-fold. As a result of the loss of activity of the enzyme flippase, which contributes to maintain the membrane asymmetry characteristic of resting cells, MPs expose on their surface the negatively charged phospholipids, such as phosphatidylserine (PS), normally segregated in the inner leaflet. 1 PS is an essential component of the multi-molecular complexes tenase and prothrombinase, which activate factor X and factor II (prothrombin) into factor Xa and factor IIa (thrombin), respectively, as well as of the tissue factor (TF)/factor VII(a) complex. 6 In the absence of primary in vivo data, it is still generally assumed that activated platelets represent the main source of PS in the coagulation process, but the possible contribution of MPs as sources of PS has long been recognized 7 and is now becoming more appreciated. 2, 8 Furthermore, MPs potentially carry TF on their membranes. 9, 10 TF is an integral membrane protein that functions as an essential cofactor for factor VII(a) and is involved in the initiation of the coagulation cascade. 11 Over the last decade, the classical view of TF as a protein only expressed in subendothelial tissues (except in rare and severe thrombotic states), and therefore 'extrinsic' to blood, has been challenged by the demonstration that functionally active TF circulates in normal blood; 12 it is now believed that this 'blood-borne' TF is mostly bound to MPs. 10, 13 As MPs can also carry the adhesion molecule P-selectin glycoprotein ligand-1 (PSGL-1), whose cognate receptor, P-selectin, is overexpressed by the activated endothelium, the potential exists for TF + /PSGL-1 + MPs to be concentrated at sites of vascular damage, thus reaching a critical concentration capable of triggering the coagulation cascade. 14, 15 The observation that the number of circulating MPs is increased in thrombotic disorders is consistent with an in vivo role of these structures in blood coagulation. 16, 17 As already mentioned, generation of MPs requires either cell activation or apoptosis. 18 An increase in cytosolic calcium concentration ([Ca 2+ ] i ) represents one of the first signs of cell activation, which leads to cell vesiculation through activation of calpain and degradation of the cytoskeleton.
19
Peroxisome proliferator-activated receptor-g (PPAR-g) is a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily and involved in the regulation of carbohydrate and lipid metabolism. 20 Synthetic agonists of PPAR-g, such as rosiglitazone (Rz) and pioglitazone (Pio), have been approved as anti-diabetic drugs. However, Rz has been subsequently subjected to restrictions, both in the USA 21 and in Europe, 22 following the observation that it increases the risk of myocardial infarction. The reasons for such increased risk are not fully understood. 23 As Rz causes a transient increase in [Ca 2+ ] i in human monocytes, thus inhibiting actin polymerization, 24 we speculated that this PPAR-g agonist, and possibly others, might influence the release of procoagulant MPs by these cells. 
Methods

Reagents and kits
Isolation and culture of monocytes/ macrophages
Monocytes/macrophages were isolated either from fresh buffy coats obtained from the local blood bank or from the peripheral blood of normal volunteers, as previously described. 25 The procedure was approved by the local ethics committee and was in accordance with the Declaration of Helsinki. Briefly, a fresh buffy coat was 
Platelet isolation
Human platelets were isolated by differential centrifugation. Briefly, platelet-rich plasma, obtained after centrifugation of citrated blood at 200 × g for 15 min, was centrifuged for 5 min at 12 000 × g. The pellet was resuspended to the desired concentration in 0.15 M NaCl.
Generation and purification of MPs
Monocytes/macrophages were washed three times with pre-warmed serum-free RPMI. For MP generation, Rz, 15d-PGJ 2 , or Pio was added in the presence or in the absence of GW9662 (a PPAR-g antagonist) or EGTA (a calcium chelator) or PD98059 (a selective non-competitive inhibitor of the MAPK pathway); after 1 h at 378C the supernatant was recovered, cleared by centrifugation at 14 000 × g for 5 min at room temperature to remove dead cells and big cell fragments that might have detached during the stimulation, and immediately used for further experiments. In selected experiments, MP-containing supernatants (12 mL) were further purified by ultracentrifugation (100 000 × g for 2 h, 48C); the pellet was resuspended in 250 mL of normal saline and used in a one-stage clotting assay to measure TF-dependent coagulation (see below, section 2.7).
Measurement of MPs
PS-positive MPs in each sample were detected using the Zymuphen MP-Activity kit (Hyphen BioMed, Neuville-sur-Oise, France) according to the kit's instructions, and expressed as PS equivalents (nanomolar). Briefly, the assay is based on the properties of annexin V, immobilized onto plastic wells, to bind PS. Monocyte/macrophage supernatant was added to the wells and, after extensive washing, captured MPs were detected by the addition of coagulation factor Va, factor Xa, Ca 2+ , and
prothrombin. In the conditions used, the rate of thrombin formation is limited by PS availability and is therefore proportional to MP concentration. A chromogenic substrate was finally added to quantify thrombin concentration with a microplate reader (Titertek Multiskan MCC ELISA reader; Flow Laboratories, McLean, VA, USA). As the assay depends on the availability of calcium ions, in the experiments in which EGTA was used during MP generation, 10 mM CaCl 2 was added prior to MP analysis. 
Measurement of intracellular calcium concentration
Assessment of MP-bound TF activity
TF activity was measured in MPs generated from human monocytes/ macrophages by a one-stage clotting time assay, as previously described, 26 except that plasma rendered MP free by ultracentrifugation (100 000 × g for 2 h) was used instead of normal plasma. Briefly, normal, MP-free, human plasma (100 mL) was added to MPs (100 mL) in a 378C bath. Calcium chloride (100 mL; 25 mM) was then added, and time to formation of a visible clot upon recalcification was recorded. The results are expressed in arbitrary units (a.u.) of procoagulant activity by comparison with a standard curve obtained using a human brain thromboplastin standard. This preparation is assigned a value of 1000 a.u. for a clotting time of 30 s. An anti-human TF antibody was used to assess the specificity of the test. 27 
Western blot analysis for detection of phosphorylated ERK1/2
Monocytes/macrophages (4 × 10 7 ) were seeded in 10 cm 2 culture dishes and, after overnight incubation, washed three times with pre-warmed serum-free RPMI and then treated with Rz,15d-PGJ 2 , Pio, or phorbol-12-myristate-13-acetate (as positive a control) for 30 min. At the end of the treatment period, the cells were washed with ice-cold PBS and detached with 35 mL of lysis buffer, a solution containing 20 mM Tris-HCl (pH 7.5), 10% glycerol, 137 mM NaCl, 10% sodium dodecyl sulphate, 1% Triton X-100, 10 mM EDTA, and protease inhibitors (1 mg/mL aprotinin, 1 mg/mL pepstatin A, 1 mg/mL leupeptin, and 1 mM phenylmethylsulphonyl fluoride). The cell lysate was cleared by centrifugation at 14 000 × g for 30 min at 48C. The protein content in the supernatant fraction was determined by a commercially available kit based on the Bradford method (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's directions. Equal amounts of sample lysate (20 -30 mg) were subjected to 7.5% sodium dodecyl sulphate-polyacrylamide gel electrophoresis according to Laemmli, 28 and the proteins were transferred onto pure nitrocellulose membranes (Bio-Rad Laboratories).
Membranes were blocked with 5% non-fat dry milk (Bio-Rad Laboratories) in tris buffered saline-Tween containing 0.5% Tween 20, 50 mM Tris -HCl (pH 7.6) and 150 mM NaCl for 24 h at 48C and were then incubated with a mouse anti-phosphorylated ERK1/2 (anti-p-ERK1/2; 1:300 dilution) overnight at 48C. The membranes were then incubated with an antibody against a-tubulin (1:3000 dilution) for 1 h at 378C to confirm equal protein loading. At the end of this period, the membranes were incubated with a horseradish peroxidase-conjugated goat antimouse antibody (1:1000 dilution) for 2 h at 378C. Finally, the membranes were washed twice with tris buffered saline-Tween and once with tris buffered saline. The immunoreactive bands were visualized using an electrochemiluminescence western blotting detection reagent according to the manufacturer's instructions. Band intensity was calculated using image analysis software (ImageJ version 1.42q; NIH, Bethesda, MD, USA).
Flow cytometric analysis of MPs
To characterize the MPs generated from monocytes/macrophages, samples were analysed by flow cytometry using FACSCalibur (Becton Dickinson, Oxford, UK). Data analysis was performed using WinMDi 2.9 software (Joseph Trotter, The Scripps Research Institute, La Jolla, CA, USA). MP-containing supernatants (12 mL) were submitted to ultracentrifugation (100 000 × g for 2 h, 48C), and the pellet was resuspended in 2 mL RPMI. One-hundred microlitres of MP was added for 30 min on ice to a phycoerythrin-conjugated antibody against CD14 (DakoCytomation, Glostrup, Denmark). Incubation was performed in the dark, and the expression of the surface marker was analysed. CD14 positivity was defined on phycoerythrin fluorescence vs. forward scatter dot plot representations. Regions corresponding to MPs were defined on forward vs. side-angle light scatter intensity dot plot representations. The forward light scatter setting was E-01, and a total of 10 000 events were analysed.
Data presentation and statistical analysis
Unless otherwise indicated, data are shown as means + SEM from n independent, consecutive experiments; comparisons among groups were made by either ANOVA for repeated measures followed by Bonferroni's analysis or Student's paired t-test, as appropriate, using Prism Software (GraphPad, San Diego, CA, USA). Values of P , 0.05 were considered statistically significant.
Results
Rz and 15d-PGJ 2 , but not Pio, induce the generation of procoagulant MPs by monocytes/macrophages
To investigate whether PPAR-g agonists induce the release of MPs, monocytes/macrophages were stimulated with different concentrations of Rz, of the naturally occurring PPAR-g agonist, 15d-PGJ 2 , and of Pio for 1 h; the supernatants were collected, and MPs were quantified as nanomolar PS. As shown in Figure 1 , monocytes/macrophages generate MPs upon stimulation with both Rz (Figure 1A and D) and 15d-PGJ 2 ( Figure 1B and E) in a dose-dependent manner; the effect reached statistical significance at 80 mM for Rz and at 20 mM for 15d-PGJ 2 . In contrast, Pio did not exert any effect at the highest concentration (80 mM; Figure 1C) .
The cellular origin of these MPs was analysed by flow cytometry. As shown in Figure 1F , approximately 96% of MPs were CD14 positive, confirming their monocytic origin.
Role of Ca 21 mobilization in Rz-and 15d-PGJ 2 -induced generation of MPs by monocytes/macrophages
The mechanisms that regulate the generation of MPs are not completely defined; however, it is known that MPs are released following activation or cell death, the latter being due to either apoptosis or necrosis. 18 Mobilization of Ca 2+ is a critical step in the cell activation process. To investigate whether PPAR-g agonists affect intracellular calcium mobilization, monocytes/macrophages were loaded with Fluo-4 NW probe and stimulated with Rz, 15d-PGJ 2 , or Pio. Our data show that Rz (80 mM) and 15d-PGJ 2 (20 mM), but not Pio (80 mM), induce a rapid increase in [Ca 2+ ] i observed over time.
The calcium ionophore, A23187 (12 mM), was used as a positive control (Figure 2) . To investigate the role of Ca 2+ mobilization in generation of MPs further, the calcium chelator, EGTA, was used. The addition of EGTA prior to monocyte/macrophage stimulation with Rz or 15d-PGJ 2 largely inhibited MP generation (Figure 3 ).
Effect of PPAR-g inhibition on shedding of MPs stimulated by PPAR-g
PPAR-g agonists have been shown to exert some effects independent of PPAR-g activation. 29 -31 To investigate the role of PPAR-g activation, the specific inhibitor, GW9662, was used. GW9662 did not affect intracellular calcium mobilization induced by either Rz or 15d-PGJ 2 (see Supplementary material online, Figure S1 ); however, GW9662 caused a significant inhibition of the MP generation induced by Rz and 15d-PGJ 2 ( Figure 4) . T. Neri et al.
Role of ERK in PPAR-g agonist-induced MP release
PPAR-g agonists are also known to stimulate MAPK activities in certain cell lines. 32 We sought to investigate whether ERK phosphorylation is involved in Rz-and 15d-PGJ 2 -induced shedding of MPs. Figure 5A shows that both Rz and 15d-PGJ 2 induce ERK phosphorylation in monocytes/macrophages. Furthermore, the selective noncompetitive inhibitor of the MAPK pathway, PD98059, inhibits MP generation ( Figure 5B) . In contrast to Rz and 15d-PGJ 2 , Pio did not induce ERK phosphorylation ( Figure 5C ), consistent with the hypothesis that ERK phosphorylation is involved in Rz-and 15d-PGJ 2 -mediated MP generation. The procoagulant activity of MPs is due to the exposure of PS on their surface and is also enhanced by the presence of functional TF. 15 To evaluate whether Rz and 15d-PGJ 2 induce the generation of TF-bearing MPs by monocytes/macrophages, we analysed the procoagulant activity of purified MPs released by treated and untreated cells through a onestage clotting test. As shown in Figure 6 , Rz and 15d-PGJ 2 induce a 2-to 2.5-fold increase in procoagulant activity of MPs. A monoclonal antibody to TF (epitope specific for amino acids 1-25; American Diagnostica, Stamford, CT, USA; 30 mg/mL) inhibited most of the procoagulant activity (not shown), confirming the identity of this activity with TF. In contrast, Pio did not exert any effect. The MAPK inhibitor, PD98059, and the specific PPAR-g inhibitor, GW9662, inhibited the up-regulation of the expression of MP-bound TF.
As platelets respond to numerous different stimuli with the generation of TF-bearing MPs, 10 we performed experiments in which a number of platelets corresponding to 10 times the number of mononuclear cells were treated exactly as described for mononuclear cells. In our hands, contaminating platelets are consistently less than two per mononuclear cell, so that the number of platelets used in our experiments is in large excess compared with the number of platelets that can potentially contaminate our preparations. We could not detect any significant generation of MP-bound TF upon incubation with rosiglitazone (not shown).
Discussion
The aim of this work was to investigate whether Rz and other PPAR-g agonists might influence release of procoagulant MPs by human monocytes/macrophages. Our results show that, indeed, the thiazolidinedione, Rz, as well as the naturally occurring agonist, 15d-PGJ 2 , cause an increased release of MP. It has previously been shown that Rz causes an increase in intracellular calcium in monocytes, and that this property of Rz is responsible for an inhibition in actin polymerization. 24 In turn, it is known that destabilization of the actin cytoskeleton, at least in platelets, causes disconnection of the plasma membrane and MP formation. 33 Thus, the present data, including the demonstration that Rz and 15d-PGJ 2 cause an increase in [Ca 2+ ] i , are consistent with the hypothesis that PPAR-g activation stimulates MP shedding in monocytes/macrophages through calcium mobilization. The demonstration that EGTA largely inhibits the effect lends further support to this hypothesis. However, we also show that the PPAR-g inhibitor, GW9662, does not affect calcium mobilization while still inhibiting MP formation, which indicates that PPAR-g agonist-induced MP shedding via calcium mobilization is independent of ligand-receptor interaction. A recent report by Li et al. has demonstrated the involvement of the ERK pathway in the generation of MPs by human monocytes stimulated with cigarette smoke extract. 34 As PPAR-g agonists induce ERK phosphorylation, 32 we speculated that the ERK pathway might be involved in the generation of MPs induced by PPAR-g agonists. Our data showing that ERK is phosphorylated by PPAR-g agonists and that ERK inhibition abolishes MP generation are indeed consistent with the hypothesis.
Thus, it appears that Rz and 15d-PGJ 2 stimulate MP formation through at least two distinct mechanisms, one dependent on calcium mobilization, largely independent of the PPAR-g receptor, and possibly mediated through ERK phosphorylation, 35, 36 and one mediated through the activation of the PPAR-g receptor.
In conclusion, we demonstrate that two structurally unrelated PPAR-g agonists, the member of the thiazolidinedione family, Rz, and the naturally occurring prostaglandin, 15d-PGJ 2 , up-regulate the expression of procoagulant, TF-bearing MPs by human monocytes/ macrophages through both a PPAR-g activation-independent increase in [Ca 2+ ] i and a PPAR-g activation-dependent mechanism. Another member of the thiazolidinedione family, namey Pio, failed to show the same effect. Differences among members of this family in terms of biological activity have been reported. Regarding calcium handling, a recent study aimed to investigate the chemical sensing profiles of transient receptor potential (TRP) channels, for example, has led to the observation that Rz causes an increase in [Ca 2+ ] i in cells overexpressing TRP canonical 5 (TRPC5) channel. In contrast, Pio, as well as two other members of the same family, troglitazone and ciglitazone, completely failed to evoke TRPC5 activity. The specific requirements for TRCP5 channel activation were not investigated further, but the authors conclude that the thiazolidinedione moiety is insufficient for TRPC5 modulation. 37 In light of the growing interest in MPs as physiologically relevant effectors in human blood coagulation, these data add to our knowledge on the mechanisms underlying their generation.
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